865234-02-2

Basic information

• Product Name: Methyl3-(4-hydroxyphenyl)hex-4-ynoate
• Synonyms: Methyl3-(4-hydroxyphenyl)hex-4-ynoate
• CAS NO: 865234-02-2
• Molecular Formula: C₁₃H₁₄O₃
• Molecular Weight: 218.24846
• Mol File: 865234-02-2.mol

Chemical Properties

• Boiling Point: 355.7±37.0 °C(Predicted)
• Appearance: /
• Density: 1.144±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 9.71±0.26(Predicted)
• CAS DataBase Reference: Methyl3-(4-hydroxyphenyl)hex-4-ynoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl3-(4-hydroxyphenyl)hex-4-ynoate(865234-02-2)
• EPA Substance Registry System: Methyl3-(4-hydroxyphenyl)hex-4-ynoate(865234-02-2)

Safety Data

• Hazardous Substances Data: 865234-02-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 3-(4-hydroxyphenyl)hex-4-ynoate is used as a pharmaceutical intermediate for the synthesis of various drugs and active pharmaceutical ingredients. Its unique structure and functional groups make it a valuable building block in the development of new medications.
Used in Cosmetics Industry:
Methyl 3-(4-hydroxyphenyl)hex-4-ynoate is used as an active ingredient in cosmetics for its potential antioxidant and anti-aging properties. The presence of the hydroxyl group attached to the phenyl ring may contribute to its ability to protect the skin from oxidative stress and promote collagen synthesis.
Used in Organic Synthesis:
Methyl 3-(4-hydroxyphenyl)hex-4-ynoate is used as a key intermediate in the synthesis of various organic compounds, including specialty chemicals, dyes, and other complex molecules. Its unique structure and reactivity make it a versatile building block in organic chemistry.

Upstream product

• 865233-34-7 4-hydroxy-β-1-propyn-1-ylbenzenepropanoic acid 
• 74-88-4 methyl iodide 
• 123-08-0 4-hydroxy-benzaldehyde 
• 17474-27-0 5-(4-hydroxy-benzylidene)-2,2-dimethyl-[1,3]dioxane-4,6-dione 
• 865233-33-6 (+/-)-5-[1-(4-hydroxy-phenyl)-but-2-ynyl]-2,2-dimethyl-[1,3]dioxane-4,6-dione 
• 67-56-1 methanol 

Downstream Products

• 1312791-61-9 C₂₀H₁₇NO₄ 
• 1312791-71-1 methyl 3-[4-(benzyloxy)phenyl]hex-4-ynoate 
• 1353043-43-2 methyl 3-[4-(6-bromo-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethoxy)phenyl]hex-4-ynoate 
• 1353043-41-0 Methyl 3-[4-(5-bromo-3,3-dimethyl-2-oxo-2,3-dihydroindol-1-ylmethoxy)phenyl]hex-4-ynoate 
• 929712-54-9 (+/-)-Methyl 3-(4-(4-phenylcyclohexyloxy)phenyl)hex-4-ynoate 
• 865233-62-1 3-(3-nitro-4-hydroxy-phenyl)-hex-4-ynoic acid methyl ester 
• 1353893-60-3 methyl 3-[4-(1-hydroxymethylcyclopropylmethoxy)phenyl]hex-4-ynoate 
• 1353893-57-8 methyl 3-{4-[1-(3-tert-butylphenoxymethyl)cyclopropylmethoxy]phenyl}hex-4-ynoate 
• 1354028-26-4 Methyl 3-{4-[2-mehtyl-3-(4-trifluoromethylphenoxy)propoxy]phenyl}hex-4-ynoate 

Relevant articles and documents

Discovery of novel potent GPR40 agonists containing imidazo[1,2-a]pyridine core as antidiabetic agents

Free fatty acid receptor 1 (FFA1 or GPR40) has been studied for many years as a target for the treatment of type 2 diabetes mellitus. In order to increase potency and reduce hepatotoxicity, a series of novel compounds containing imidazo[1,2-a]pyridine sca

A class of GPR40 agonist compounds with amide structure, and uses thereof

The present invention relates to a class of amide compounds with a novel structure, and a pharmaceutical composition thereof, wherein the structure of the amide compound is represented by a general formula (I). According to the present invention, the amide compound (I) can regulate GPR40 activity, and can be used for GPR40 activity related diseases such as diabetes and metabolic syndrome. The formula I is defined in the specification.

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER

New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I, Formula I.1, Formula I.2, Formula IA, Formula IB, Formula IC and Formula II and their pharmaceutical acceptable salts for the treatment of cancer. The use of

AGONISTS OF GPR40

The present invention relates to compounds that have the ability to modulate the activity of GPR40 and are there-fore useful in the treatment of GPR40 related disorders. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders related to GPR40 activity.

3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists

The design, synthesis, and structure-activity relationship (SAR) for a series of β-substituted 3-(4-aryloxyaryl)propanoic acid GPR40 agonists is described. Systematic replacement of the pendant aryloxy group led to identification of potent GPR40 agonists. In order to identify candidates suitable for in vivo validation of the target, serum shifted potency and pharmacokinetic properties were determined for several compounds. Finally, further profiling of compound 7 is presented, including demonstration of enhanced glucose tolerance in an in vivo mouse model.